Status:
RECRUITING
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Lead Sponsor:
Christopher Kai Shun Leung
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-a...
Detailed Description
This prospective randomized, double-blind, placebo-controlled clinical trial evaluates four nicotinamide adenine dinucleotide (NAD) precursors for neuroenhancement in 138 adults with primary open-angl...
Eligibility Criteria
Inclusion
- glaucoma patients
- age ≥ 18 years
- best corrected VA ≥20/40
- IOP \<21 mmHg
- visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard
Exclusion
- pathological myopia
- diseases that may cause visual field loss or optic disc abnormalities other than glaucoma
- inability to perform reliable visual field
- suboptimal quality of OCT images
- diabetic retinopathy/maculopathy
- history of abnormal liver function within 12 months
- known allergy to NAD precursor supplement(s)
- pregnancy or lactation
- use of NAD precursor supplements 14 days prior to baseline.
Key Trial Info
Start Date :
May 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT06991712
Start Date
May 19 2025
End Date
December 31 2026
Last Update
June 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HKU Eye Centre
Wong Chuk Hang, Hong Kong